Orexigen Therapeutics (OREX) Misses Q4 EPS by 21c
Get Alerts OREX Hot Sheet
Financial Fact:
Collaborative agreement: 895K
Today's EPS Names:
CPSS, HARL, MCET, More
Join SI Premium – FREE
Orexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of $0.00, $0.21 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $22.95 million versus the consensus estimate of $49.65 million.
Contrave (naltrexone HCl / bupropion HCl extended release):
Orexigen's partner for North America, Takeda Pharmaceuticals, launched Contrave in the United States on October 20, 2014. U.S. net sales for the fourth quarter, recorded by Takeda, were $6.5 million, for which Orexigen earned $1.3 million in royalties. Gross sales for the quarter were $12.3 million.
Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equifax (EFX) shares tumble as Q2, full-year guidance falls short
- First Bancorp (FNLC) Reports Q1 EPS of $0.54
- Alcoa (AA) Misses Q1 EPS by 19c
Create E-mail Alert Related Categories
Earnings, Trader TalkRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!